CLINICAL_TRIALS
trial_result
· 2024-02-12
Clinical Trial Update: A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer [Phase 2]
Summary
Phase 2 trial of AL101 monotherapy in notch-activated triple-negative breast cancer has been terminated; results posted in 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ayala Pharmaceuticals, Inc, | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-02-12